ACLARIS THERAPEUTICS INC (ACRS) Stock Fundamental Analysis

NASDAQ:ACRS • US00461U1051

3.205 USD
+0.04 (+1.1%)
Last: Feb 19, 2026, 11:58 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

ACRS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. While ACRS seems to be doing ok healthwise, there are quite some concerns on its profitability. ACRS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year ACRS has reported negative net income.
  • ACRS had a negative operating cash flow in the past year.
  • In the past 5 years ACRS always reported negative net income.
  • ACRS had a negative operating cash flow in each of the past 5 years.
ACRS Yearly Net Income VS EBIT VS OCF VS FCFACRS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

  • ACRS's Return On Assets of -80.71% is on the low side compared to the rest of the industry. ACRS is outperformed by 74.35% of its industry peers.
  • With a Return On Equity value of -117.97%, ACRS is not doing good in the industry: 65.44% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -80.71%
ROE -117.97%
ROIC N/A
ROA(3y)-46.3%
ROA(5y)-49.43%
ROE(3y)-61.73%
ROE(5y)-73.31%
ROIC(3y)N/A
ROIC(5y)N/A
ACRS Yearly ROA, ROE, ROICACRS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

  • ACRS has a Gross Margin of 3.98%. This is comparable to the rest of the industry: ACRS outperforms 50.79% of its industry peers.
  • In the last couple of years the Gross Margin of ACRS has grown nicely.
  • The Profit Margin and Operating Margin are not available for ACRS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 3.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.2%
GM growth 5Y35.7%
ACRS Yearly Profit, Operating, Gross MarginsACRS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • ACRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ACRS has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, ACRS has more shares outstanding
  • There is no outstanding debt for ACRS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ACRS Yearly Shares OutstandingACRS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ACRS Yearly Total Debt VS Total AssetsACRS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • ACRS has an Altman-Z score of -4.49. This is a bad value and indicates that ACRS is not financially healthy and even has some risk of bankruptcy.
  • ACRS's Altman-Z score of -4.49 is on the low side compared to the rest of the industry. ACRS is outperformed by 60.73% of its industry peers.
  • ACRS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.49
ROIC/WACCN/A
WACC9.23%
ACRS Yearly LT Debt VS Equity VS FCFACRS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • A Current Ratio of 3.92 indicates that ACRS has no problem at all paying its short term obligations.
  • The Current ratio of ACRS (3.92) is comparable to the rest of the industry.
  • A Quick Ratio of 3.92 indicates that ACRS has no problem at all paying its short term obligations.
  • ACRS's Quick ratio of 3.92 is fine compared to the rest of the industry. ACRS outperforms 60.73% of its industry peers.
Industry RankSector Rank
Current Ratio 3.92
Quick Ratio 3.92
ACRS Yearly Current Assets VS Current LiabilitesACRS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The earnings per share for ACRS have decreased strongly by -165.38% in the last year.
  • ACRS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -41.87%.
  • ACRS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 34.65% yearly.
EPS 1Y (TTM)-165.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.09%
Revenue 1Y (TTM)-41.87%
Revenue growth 3Y40.43%
Revenue growth 5Y34.65%
Sales Q2Q%-24.09%

3.2 Future

  • ACRS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.96% yearly.
  • ACRS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 29.77% yearly.
EPS Next Y64.01%
EPS Next 2Y26.24%
EPS Next 3Y15.75%
EPS Next 5Y8.96%
Revenue Next Year-27.07%
Revenue Next 2Y-17.95%
Revenue Next 3Y-8.23%
Revenue Next 5Y29.77%

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
ACRS Yearly Revenue VS EstimatesACRS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M
ACRS Yearly EPS VS EstimatesACRS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 1 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ACRS. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACRS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACRS Price Earnings VS Forward Price EarningsACRS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACRS Per share dataACRS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

  • ACRS's earnings are expected to grow with 15.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.24%
EPS Next 3Y15.75%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ACRS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ACLARIS THERAPEUTICS INC

NASDAQ:ACRS (2/19/2026, 11:58:36 AM)

3.205

+0.04 (+1.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)03-03
Inst Owners80.57%
Inst Owner Change1.04%
Ins Owners2.6%
Ins Owner Change4.42%
Market Cap347.26M
Revenue(TTM)15.74M
Net Income(TTM)-141.68M
Analysts84.29
Price Target7.82 (143.99%)
Short Float %4.75%
Short Ratio2.57
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.46%
Min EPS beat(2)4.07%
Max EPS beat(2)12.85%
EPS beat(4)2
Avg EPS beat(4)-84.06%
Min EPS beat(4)-353.03%
Max EPS beat(4)12.85%
EPS beat(8)5
Avg EPS beat(8)-248.11%
EPS beat(12)9
Avg EPS beat(12)-161.66%
EPS beat(16)13
Avg EPS beat(16)-117.11%
Revenue beat(2)2
Avg Revenue beat(2)78.57%
Min Revenue beat(2)26.93%
Max Revenue beat(2)130.22%
Revenue beat(4)4
Avg Revenue beat(4)124.24%
Min Revenue beat(4)11.41%
Max Revenue beat(4)328.42%
Revenue beat(8)7
Avg Revenue beat(8)123.77%
Revenue beat(12)10
Avg Revenue beat(12)148.98%
Revenue beat(16)11
Avg Revenue beat(16)175.64%
PT rev (1m)0%
PT rev (3m)-2.42%
EPS NQ rev (1m)1.67%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.3%
Revenue NQ rev (1m)6.88%
Revenue NQ rev (3m)9.31%
Revenue NY rev (1m)0%
Revenue NY rev (3m)44.95%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 22.06
P/FCF N/A
P/OCF N/A
P/B 2.89
P/tB 2.89
EV/EBITDA N/A
EPS(TTM)-1.38
EYN/A
EPS(NY)-0.61
Fwd EYN/A
FCF(TTM)-0.74
FCFYN/A
OCF(TTM)-0.4
OCFYN/A
SpS0.15
BVpS1.11
TBVpS1.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -80.71%
ROE -117.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 3.98%
FCFM N/A
ROA(3y)-46.3%
ROA(5y)-49.43%
ROE(3y)-61.73%
ROE(5y)-73.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.2%
GM growth 5Y35.7%
F-Score2
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7420.2%
Cap/Sales 233.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.92
Quick Ratio 3.92
Altman-Z -4.49
F-Score2
WACC9.23%
ROIC/WACCN/A
Cap/Depr(3y)1560.12%
Cap/Depr(5y)949.63%
Cap/Sales(3y)66.06%
Cap/Sales(5y)41.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-165.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.09%
EPS Next Y64.01%
EPS Next 2Y26.24%
EPS Next 3Y15.75%
EPS Next 5Y8.96%
Revenue 1Y (TTM)-41.87%
Revenue growth 3Y40.43%
Revenue growth 5Y34.65%
Sales Q2Q%-24.09%
Revenue Next Year-27.07%
Revenue Next 2Y-17.95%
Revenue Next 3Y-8.23%
Revenue Next 5Y29.77%
EBIT growth 1Y-67.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-17.73%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y13.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y52.67%
OCF growth 3YN/A
OCF growth 5YN/A

ACLARIS THERAPEUTICS INC / ACRS FAQ

What is the fundamental rating for ACRS stock?

ChartMill assigns a fundamental rating of 3 / 10 to ACRS.


What is the valuation status of ACLARIS THERAPEUTICS INC (ACRS) stock?

ChartMill assigns a valuation rating of 0 / 10 to ACLARIS THERAPEUTICS INC (ACRS). This can be considered as Overvalued.


Can you provide the profitability details for ACLARIS THERAPEUTICS INC?

ACLARIS THERAPEUTICS INC (ACRS) has a profitability rating of 1 / 10.


What is the financial health of ACLARIS THERAPEUTICS INC (ACRS) stock?

The financial health rating of ACLARIS THERAPEUTICS INC (ACRS) is 6 / 10.